Now showing items 1-2 of 2

    • Lack of association between the MDM2-SNP309 polymorphism and breast cancer risk 

      Petenkaya, A.; Bozkurt, B.; Akilli-Ozturk, O.; Kaya, H. S.; Gur-Dedeoglu, B.; Yulug, I. G. (Delinasios GJ & CO, 2006)
      Background: A T-to-G polymorphism (SNP309) at the promoter region of MDM2 has been recently reported to extend the Sp1 binding site that positively regulates the MDM2 transcription level and consequently, its expression ...
    • TRIB2 confers resistance to anti-cancer therapy by activating the serine/threonine protein kinase AKT 

      Hill, R.; Madureira, P. A.; Ferreira, B.; Baptista, I.; Machado, S.; Colaço, L.; Dos Santos, M.; Liu, N.; Dopazo, A.; Ugurel, S.; Adrienn, A.; Kiss-Toth, E.; Isbilen, M.; Gure, A. O.; Link, W. (Nature Publishing Group, 2017)
      Intrinsic and acquired resistance to chemotherapy is the fundamental reason for treatment failure for many cancer patients. The identification of molecular mechanisms involved in drug resistance or sensitization is imperative. ...